Navigation Links
Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
Date:8/19/2008

DURHAM, N.C., Aug. 19 /PRNewswire/ -- Addrenex Pharmaceuticals ( http://www.addrenex.com ) has made three strategic hires this month to further its goal of identifying and developing as many new drug candidates as possible over the next 18 months.

The fast-paced timeline they have set for drug discovery mirrors the company's recent successes in developing two new drugs, Clonicel(R) for attention deficit/hyperactivity disorder and CloniBID for hypertension, over the past two years. A new drug application has already been filed for CloniBID, with Food and Drug Administration review expected by December 2008, and Clonicel is in phase 3 clinical trials. Commercial rights to both drugs have been granted to Atlanta-based Sciele Pharma.

The additions of Steven Butts, M.B.A., as vice president of commercial operations and Gary Bream, Ph.D., as senior director of scientific affairs will strengthen Addrenex's ability to pursue additional drugs to treat conditions such as menopausal flushing, pain, addiction, aggression, and post traumatic stress disorder, said Moise Khayrallah, Ph.D., cofounder and chief executive officer of Addrenex. Yuki Prescott has also joined as clinical trials manager and will enhance the clinical team's ability to oversee a growing clinical program.

"We now have a solid partnership in place with Sciele that will enable us to develop our lead compounds and to pursue additional compounds in our portfolio that target the alpha-2 adrenergic receptors," said Khayrallah. "We're using our lead compounds to power the rest of the portfolio. The highly skilled team we have now assembled gives us the capability to deliver on our commitments and meet our fast-paced timelines."

The indications being targeted by Addrenex are each associated with an overactive adrenergic system, a group of hormones produced by the adrenal glands that regulate the body's reaction to stress, hormonal
'/>"/>

SOURCE Addrenex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
2. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
5. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
6. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
9. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
11. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...., Nov. 19 Amgen,(Nasda...mpany, a subsidiary of,Takeda Pharmaceutical Comp...ollment in the Phase 3 MONET1 trial evaluating mot...nd carboplatin for the first-line treatment of,ad... temporarily suspended,following a planned safety...
(Date:11/19/2008)...Nov. 19 Biotech scientists increas...logy research to better understand the effects of ...s, reports Genetic Engineering & Biotechnolog... figuring out a new compound,s mechanism of action... technique, according to the November 15 issue of ...
(Date:11/18/2008)... NeuroDiscovery Ltd (ASX:...and drug development Company,and Sosei Group Cor...ding,international biopharmaceutical company, tod...ther pivotal pre-clinical efficacy data for NSL-04... therapy for neuropathic pain and has,successfull...
(Date:11/18/2008)... 18 Forty-two leading U...mber national forum to consider cutting-edge innov... national economy from outbreaks of dangerous zoon... , Among those innovations: , , , ...hen table that detects highly contagious and dange...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7GEN Reports on the Trend Toward Predictive Toxicogenomics 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2International Aid Named as a MinistryWatch com Shining Light Christian Ministry 8404 1International Aid Named as a MinistryWatch com Shining Light Christian Ministry 8404 2IQS Donates Quality Management Software to Family Health International 8402 1IQS Donates Quality Management Software to Family Health International 8402 2IQS Donates Quality Management Software to Family Health International 8402 3Genome Technology Magazine Names Top Young Investigators of 2007 2246 1Genome Technology Magazine Names Top Young Investigators of 2007 2246 2Robin C Stracey Joins Cantimer Inc as President and CEO 2244 1Robin C Stracey Joins Cantimer Inc as President and CEO 2244 2
...novative technology has enabled more and more labo...ns office, the central laboratory is hardly threat... that medium and large labs are busier than ever b...old standard reliability and ability to handle ver...nd pivotal position in the clinical landscape. ,...
...rus (EBV), which causes infectious mononucleosis (...occurs worldwide, and most people become infected ...d States, as many as 95 percent of adults between ... developed countries, including the U.S., infectio... young adulthood, causing infectious mononucleosis...
Other Medicine Technology:When Volume Matters, Immunoassay Systems Deliver 2When Volume Matters, Immunoassay Systems Deliver 3Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies 2Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies 3
(Date:11/21/2008)...008)The University of Texas Health Science Center ...ellence in Aging Studies (TEXAS), to promote geria...s $2 million award from the Donald W. Reynolds Fou...is will allow us to teach geriatric medicine princ...dent to practicing physicians. With the reach of L...
(Date:11/21/2008)...ain cautious about future antibiotic resistance fr...(HealthDay News) -- People with moderate to severe...be able to reduce the frequency of exacerbations t... a new report says. , The study, published in ...nal of Respiratory and Critical Care Medicine , fo...
(Date:11/21/2008)...21 NursingCenter.com, the premier ...peer reviewed content, has been,updated to improv...tered,users. Powered by Lippincott Williams &...er 900 peer-reviewed continuing education activiti...han 50 leading nursing journals.,Lippincott Willi...
(Date:11/21/2008).... 21 Barr Pharmaceutical...areholders overwhelmingly approved the proposals s...rr by Teva Pharmaceuticals Industries Ltd. (Nasdaq... the overwhelming support of the transaction by th... Chairman and CEO. "We are pleased with the progre...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
...ncephalopathy (BSE) is the condition in which ther...le. It is very fatal.// The Canadian Food Inspect...he fourth cow was tested positive for this disease...ix-years old. The results of the investigation wer...
...nternational Journal of Cancer on February 17, 200...lon cancer and the level of physical activity in w...erican women has found no such link. Experts felt... the production of prostaglandins and insulin besi...
... organically have better health value. Besides bei... insecticides they increase the nutritional value ...he globe research is being done in this field. P...e harmful chemicals over food surface and cause he...
...rt attack that are commonly referred to as non-com...Indian economy, // claiming approximately $237 of ...es by World Health Organization. While India lost...the toll might reach 60 million due to health rela...
Other Medicine News:Health News:Women, Exercise and Colon Cancer 2
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...e Dual Adaptor allows the surgeon to document proc...eo or 35mm photography. Many different types of ad...
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...ersal Microsurgical Video Adaptor (US pat. no. 5,2...both single-chip and 3CCD cameras on the same adap...
...ALLEGRO Topolyzer and T-CAT have been optimized to...rection and to interact in perfect synchronization...ll necessary treatment and patient parameters are ...GRETTO WAVE laser systems via diskette, mini CD or...
...The WaveScan WaveFront System is an ophthalmic dia...ror and wavefront aberrations of the human eye usi...ents can be used to determine regular (sphero-cyli...rrations) that cause decreased or blurry vision in...
Medicine Products: